Unlocking New Targets to Transform the Treatment of Neurodegenerative Diseases
Harness Therapeutics的外部链接
Babraham Research Campus
Minerva Building
GB，Cambridgeshire，Cambridge，CB223AT
Anyone attending BIO-Europe this week will be able to catch Harness Therapeutics CEO Jan Thirkettle who will be there engaging with partners old and new! #BIOEurope #Stockholm #GlobalPharma
Looking forwards a busy 3 days in Stockholm catching up with our current partners and meeting many more potential new ones. Lots to update on, and big plans to share for next year! ?? BIO-Europe ?? Stockholm, Sweden #BIOEurope #Stockholm #GlobalPharma
Our very own Jan Thirkettle recently took part in the Barrington James CEO series where he delved into the lessons learned from his mentors and the importance of integrity in leadership which continues to play a significant role within his principles today as CEO of Harness Therapeutics!
The wait is over! The CEO Series with Jan Thirkettle is OUT NOW! ?? Join Jan Thirkettle, CEO of Harness Therapeutics and Simon Allsop, Head of Barrington James Board & Executive Partners, as they delve into the secrets of successful leadership, people management, and creating a culture of certainty—even in times of uncertainty. Don't miss this invaluable insight into building strong, resilient teams. Watch now! ?? https://lnkd.in/eEXn3r_Z #Lifescience #CEO #TheCEOSeries #Leadership #PeopleManagement
Congratulations to Victor Ambros and Gary Ruvkun for their Nobel Prize recognising their work on miRNA and gene regulation. Fantastic to see this area of important but subtle biology being recognised in this way. At Harness Therapeutics we have been able to show that modulating miRNA regulation of protein translation can provide an important therapeutic strategy to address potentially disease-modifying targets for neurodegenerative diseases. Visit www.harnesstx.com to learn more!
BREAKING NEWS The Nobel Assembly at the Karolinska Institutet has today decided to award the 2024 Nobel Prize in Physiology or Medicine to Victor Ambros and Gary Ruvkun for the discovery of microRNA and its role in post-transcriptional gene regulation. This year’s Nobel Prize honours two scientists for their discovery of a fundamental principle governing how gene activity is regulated. The information stored within our chromosomes can be likened to an instruction manual for all cells in our body. Every cell contains the same chromosomes, so every cell contains exactly the same set of genes and exactly the same set of instructions. Yet, different cell types, such as muscle and nerve cells, have very distinct characteristics. How do these differences arise? The answer lies in gene regulation, which allows each cell to select only the relevant instructions. This ensures that only the correct set of genes is active in each cell type. This year’s medicine laureates Victor Ambros and Gary Ruvkun were interested in how different cell types develop. They discovered microRNA, a new class of tiny RNA molecules that play a crucial role in gene regulation. Their groundbreaking discovery revealed a completely new principle of gene regulation that turned out to be essential for multicellular organisms, including humans. It is now known that the human genome codes for over one thousand microRNAs. Their surprising discovery revealed an entirely new dimension to gene regulation. MicroRNAs are proving to be fundamentally important for how organisms develop and function.
Senior Scientist for Harness Therapeutics, Dr Isabela Cunha Navarro will be travelling to Montreal in Canada this weekend to attend the 20th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) 6-9 October. The event aims to bring together expertise from different angles of oligonucleotide research to create synergies and bring the field of oligonucleotides to its full therapeutic potential. Oligonucleotide therapeutics are now being used to successfully treat diseases and have the potential for widespread application. There are over 100 treatments in development for common conditions, including cancer and Alzheimer’s disease, as well as other rare diseases. The team at Harness Therapeutics are concentrating all their efforts on the physiological upregulation of targets that have the promise to provide disease-modifying therapeutics for neurodegenerative diseases such as Huntington’s disease and Alzheimer’s. We use a range of mRNA-targeted oligonucleotide-based methodologies to alter the post-transcriptional regulation of protein synthesis, increasing the target protein in a highly controlled manner so the OTS meeting in Montreal will be a very interesting for us! ?? October 6-9, 2024 ??Montreal, Canada #ots24 #oligomeeting #oligotherapeutics #oligonucleotide #OTS #biotech #science #research #biochemistry #medicine #health #biotechnology #montreal #huntingdon’s #Alzheimer’s?
Harness Therapeutics team members Laura Grasso, Zara Smith, PhD, Sinem (Nursabah) Atli, PhD and Tom Briston are attending ELRIG today, Europe’s largest drug discovery conference, where they will be networking with the life science community and being inspired by the latest research. ? The conference covers not only therapeutic themes such as mechanisms of ageing and cell & gene therapy, but also more practical aspects of drug discovery encompassing advances in assay design, applications in high content imaging, target identification and disease modelling complementary to our work in harnessing protein translation to unlock new disease-modifying targets for neurodegenerative disease. #elrig #elrigdd24 #drugdiscovery
Today is World Alzheimer’s Day. ? Here at Harness Therapeutics, we are focused on developing disease modifying therapies which can be life-changing for people with ALS, Alzheimer’s and other neurodegenerative diseases. ? The platform and unique capabilities we have built allow us to make controlled increases in targets, in a way which is suitable for the CNS targets involved in complex biology. We believe that this approach is the key to opening up new targets for neurodegeneration with approaches which can be truly disease modifying. ? Our second programme targets TDP-43 pathology in a unique way, by upregulating a nuclear import receptor linked to TDP-43 re-localisation, having a significant impact on patients with sporadic ALS and Alzheimer’s disease.
The Harness Therapeutics team took some time out to gather for a much-needed summer event yesterday afternoon at Wandlebury Country Park where we enjoyed a scrumptious picnic provided by Thoroughbreads Coffee Bar and an All-Hands presentation made by Jan Thirkettle followed by a slightly competitive game of rounders!
While they are in Strasbourg, our CSO Andy Billinton and SVP Madeleine Wakeling have been catching up with members of our Scientific Advisory Board (SAB), Irina Antonijevic, Jeff Long, Ralf Reilmann and Tom Massey. Thank you for the fantastic discussions and highly valuable input to our FAN1/HD programme as we plan for clinical development!
Our SVP Madeleine Wakeling, CSO Andy Billinton, and Research Scientist Laura Heraty are excited to be in Strasbourg this week attending the European Huntington′s Disease Network conference, engaging with experts in Huntington’s Disease research and clinical development, as we continue to drive our lead FAN1 HD programme towards the clinic. Please grab them for a chat to learn more!
Busy week ahead next week with our CEO Jan Thirkettle attending LSX World Congress in Boston and looking forwards to meeting potential partners and investors. Meanwhile, on the other side of the 'pond', SVP Madeleine Wakeling , CSO Andy Billinton and Research Scientist Laura Heraty will all be traveling to Strasbourg to attend the 2024 European Huntington′s Disease Network conference to meet an array of KOLs and experts who are helping to support Huntington’s Disease research and clinical development. Whilst there they will be meeting our SAB for its first face-to-face session. More to follow...!
Looking forwards to meeting new potential partners, and continuing conversations at LSX World Congress USA in Boston next week. Please drop me a message or an invite through the partnering app to meet. Lots of Harness news to update on with our FAN1 programme for Huntington's advancing rapidly now and our platform now delivering additional exciting and differentiated targets for #Neurodeneration! #LSXWorld https://lnkd.in/erqgC4tF LSX USA Congress